Profile data is unavailable for this security.
About the company
Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
- Revenue in USD (TTM)523.53m
- Net income in USD118.02m
- Incorporated1998
- Employees352.00
- LocationCorcept Therapeutics Inc149 Commonwealth DrMENLO PARK 94025United StatesUSA
- Phone+1 (650) 688-8803
- Fax+1 (650) 327-3218
- Websitehttps://www.corcept.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Guardant Health Inc | 563.95m | -479.45m | 2.30bn | 1.78k | -- | 14.47 | -- | 4.08 | -4.28 | -4.28 | 5.04 | 1.30 | 0.3321 | 4.00 | 6.06 | 317,002.80 | -28.23 | -22.26 | -31.99 | -24.59 | 59.74 | 64.62 | -85.02 | -97.07 | 6.24 | -12.04 | 0.8778 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
Geron Corp | 237.00k | -184.13m | 2.31bn | 141.00 | -- | 8.64 | -- | 9,732.34 | -0.3246 | -0.3246 | 0.0004 | 0.455 | 0.0008 | -- | 0.0988 | 1,680.85 | -62.99 | -51.32 | -92.09 | -64.90 | -- | -- | -77,690.72 | -19,949.13 | -- | -- | 0.2484 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
Sana Biotechnology Inc | 0.00 | -283.26m | 2.31bn | 328.00 | -- | 7.18 | -- | -- | -1.46 | -1.46 | 0.00 | 1.45 | 0.00 | -- | -- | 0.00 | -40.81 | -38.99 | -46.74 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
Vericel Corp | 197.52m | -3.18m | 2.31bn | 314.00 | -- | 10.12 | 1,476.73 | 11.72 | -0.0684 | -0.0684 | 4.15 | 4.72 | 0.6304 | 4.26 | 3.77 | 629,031.90 | -1.02 | -3.07 | -1.17 | -3.50 | 68.64 | 67.87 | -1.61 | -4.49 | 4.21 | -- | 0.0004 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
Vera Therapeutics Inc | 0.00 | -95.99m | 2.37bn | 51.00 | -- | 18.99 | -- | -- | -2.28 | -2.28 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.54 | -- | -74.10 | -- | -- | -- | -- | -- | -- | -- | 0.3291 | -- | -- | -- | -7.79 | -- | -- | -- |
Twist Bioscience Corp | 277.49m | -192.14m | 2.38bn | 919.00 | -- | 4.28 | -- | 8.59 | -3.35 | -3.35 | 4.83 | 9.63 | 0.3565 | 4.87 | 7.04 | 301,943.40 | -24.68 | -30.50 | -27.12 | -33.84 | 38.29 | 36.02 | -69.24 | -113.33 | 5.06 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
CG Oncology Inc | 204.00k | -67.80m | 2.42bn | 61.00 | -- | -- | -- | 11,847.53 | -1.07 | -1.07 | 0.0032 | 2.91 | -- | -- | -- | 3,344.26 | -- | -- | -- | -- | -- | -- | -23,826.96 | -- | -- | -- | 0.002 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
Hims & Hers Health Inc | 872.00m | -23.55m | 2.42bn | 1.05k | -- | 6.99 | -- | 2.77 | -0.1131 | -0.1131 | 4.17 | 1.61 | 2.16 | 7.13 | 195.17 | 833,652.00 | -5.83 | -- | -7.02 | -- | 81.99 | -- | -2.70 | -- | 2.74 | -- | 0.00 | -- | 65.49 | -- | 64.15 | -- | -- | -- |
Denali Therapeutics Inc | 330.53m | -145.22m | 2.44bn | 445.00 | -- | 2.30 | -- | 7.39 | -1.09 | -1.09 | 2.39 | 7.45 | 0.2529 | -- | -- | 742,766.30 | -11.11 | -14.98 | -13.37 | -17.71 | -- | -- | -43.94 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
TG Therapeutics Inc | 289.33m | 41.20m | 2.50bn | 264.00 | 73.43 | -- | 48.03 | 8.64 | 0.2205 | 0.2205 | 1.97 | -- | -- | -- | -- | 1,095,962.00 | -- | -62.87 | -- | -80.06 | 93.53 | -- | 14.24 | -405.03 | -- | 4.01 | -- | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
Avidity Biosciences Inc | 9.56m | -212.22m | 2.53bn | 253.00 | -- | 4.19 | -- | 264.57 | -2.90 | -2.90 | 0.131 | 6.32 | 0.0151 | -- | -- | 37,786.56 | -33.49 | -31.61 | -37.40 | -34.45 | -- | -- | -2,219.88 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
PTC Therapeutics, Inc. | 927.56m | -579.22m | 2.53bn | 988.00 | -- | -- | -- | 2.73 | -7.69 | -7.69 | 12.28 | -11.66 | 0.5459 | 2.33 | 4.64 | 938,823.90 | -34.09 | -26.71 | -48.63 | -33.46 | 92.88 | 93.94 | -62.45 | -83.80 | 1.98 | -0.7975 | 1.72 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
Corcept Therapeutics Incorporated | 523.53m | 118.02m | 2.55bn | 352.00 | 22.93 | 4.66 | 21.39 | 4.86 | 1.07 | 1.07 | 4.74 | 5.27 | 0.822 | 1.12 | 11.13 | 1,487,298.00 | 18.53 | 21.17 | 21.50 | 23.85 | 98.54 | 98.52 | 22.54 | 27.23 | 5.10 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
Neogen Corp | 929.24m | 1.57m | 2.60bn | 2.64k | 1,667.13 | 0.8276 | 22.09 | 2.80 | 0.0072 | 0.0072 | 4.29 | 14.52 | 0.2044 | 2.79 | 5.81 | 351,984.10 | 0.0345 | 3.44 | 0.0355 | 3.62 | 50.97 | 47.25 | 0.1685 | 7.77 | 2.66 | 1.40 | 0.2205 | 0.00 | 56.01 | 15.63 | -147.34 | -- | 25.71 | -- |
Rhythm Pharmaceuticals Inc | 77.43m | -184.68m | 2.67bn | 226.00 | -- | 15.32 | -- | 34.46 | -3.19 | -3.19 | 1.34 | 2.86 | 0.2165 | 1.61 | 7.34 | 342,601.80 | -51.64 | -47.21 | -59.55 | -52.84 | 87.99 | -- | -238.52 | -681.38 | 5.43 | -- | 0.3847 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Dec 2023 | 13.95m | 13.48% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 9.30m | 8.98% |
Ingalls & Snyder LLCas of 31 Dec 2023 | 8.35m | 8.07% |
Renaissance Technologies LLCas of 31 Dec 2023 | 6.73m | 6.50% |
Parallel Advisors LLCas of 31 Dec 2023 | 3.77m | 3.64% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 3.39m | 3.27% |
Dimensional Fund Advisors LPas of 31 Dec 2023 | 2.31m | 2.23% |
Geode Capital Management LLCas of 31 Dec 2023 | 2.05m | 1.98% |
Boston Trust Walden, Inc.as of 31 Mar 2024 | 1.84m | 1.77% |
D. E. Shaw & Co. LPas of 31 Dec 2023 | 1.66m | 1.60% |